Searchable abstracts of presentations at key conferences in endocrinology

ea0044cc3 | Featured Clinical Cases | SFEBES2016

Tremelimumab-induced Graves’ disease

Gan Earn H , Plummer Ruth , Pearce Simon , Perros Petros

Ipilimumab and tremelimumab are monoclonal antibodies directed against the extracellular domain of cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) and have been used as the immunotherapies against immune checkpoints that suppress T cell activation. These anti-CTLA4 antibody-based therapies are effective in treating various cancers including metastatic melanoma. However, a few immune-related adverse events including hypophysitis and transient thyroiditis have been reported....